Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ: NBIX )

139.44 +0.41 (+0.29%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 602,689
Open 139.09
Bid (Size) 138.10 (1)
Ask (Size) 143.00 (1)
Prev. Close 139.03
Today's Range 138.34 - 139.82
52wk Range 110.95 - 157.98
Shares Outstanding 101,200,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Neurocrine Biosciences Stock Sees RS Rating Upgrade
Neurocrine Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 67 to 71. 
Via Investor's Business Daily
While growth is established for NASDAQ:NBIX, the stock's valuation remains reasonable.
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. 
Via Chartmill

Performance

YTD
+5.85%
+5.85%
1 Month
+10.15%
+10.15%
3 Month
+21.19%
+21.19%
6 Month
+1.29%
+1.29%
1 Year
+5.52%
+5.52%

More News

Read More
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
Via Benzinga
What Analysts Are Saying About Neurocrine Biosciences Stock
Via Benzinga
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
Via Benzinga
Exposures Product Safety
NASDAQ:NBIX qualifies as a high growth stock and is consolidating.
Via Chartmill
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.
Via Chartmill
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via Chartmill
Neurocrine Wins FDA Approval For Genetic Disorder Drug
Via Investor's Business Daily
Exposures Product Safety
Screening For Black Friday Bargains In The Stock Market
Via Benzinga
For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering.
Via Chartmill
NASDAQ:NBIX stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
Via Benzinga
In-Depth Examination Of 20 Analyst Recommendations For Neurocrine Biosciences
Via Benzinga
Decoding 19 Analyst Evaluations For Neurocrine Biosciences
Via Benzinga
NASDAQ:NBIX, a growth stock which is not overvalued.
Via Chartmill
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.
Via Chartmill
NASDAQ:NBIX appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
Critical Insights From Neurocrine Biosciences Analyst Ratings: What You Need To Know
Via Benzinga
"Rule Breaker Investing" Market Cap Game Show: Throwdowns & Long-Term Wins
Via The Motley Fool
Despite its growth, NASDAQ:NBIX remains within the realm of affordability.
Via Chartmill
For those who appreciate value investing, NASDAQ:NBIX is a compelling option with its solid fundamentals.
Via Chartmill
Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint
Via Benzinga
Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio?
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.